Get the Stockscreener App
2.66
7.69%
0.19
After Hours:
2.70
0.04
+1.50%
Codexis Inc stock is traded at $2.66, with a volume of 807.54K.
It is up +7.69% in the last 24 hours and up +3.91% over the past month.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
See More
Previous Close:
$2.47
Open:
$2.47
24h Volume:
807.54K
Relative Volume:
0.72
Market Cap:
$241.78M
Revenue:
$78.09M
Net Income/Loss:
$-31.99M
P/E Ratio:
-7.3278
EPS:
-0.363
Net Cash Flow:
$-22.12M
1W Performance:
+14.16%
1M Performance:
+3.91%
6M Performance:
+54.65%
1Y Performance:
-3.97%
1-Day Range:
$2.45
$2.695
1-Week Range:
$2.175
$2.695
52-Week Range:
$0.9583
$3.87
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
2.66 | 205.43M | 78.09M | -31.99M | -22.12M | -0.363 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
Codexis Inc. (CDXS) Slips 2.5% as Shares Test Key Support LevelsVirgin POC - dars.gov.et
Enterprise value to revenue forward of Codexis, Inc. – NASDAQ:CDXS - TradingView
Enterprise value to EBITDA forward of Codexis, Inc. – NASDAQ:CDXS - TradingView
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results - 富途牛牛
Price to book forward of Codexis, Inc. – NASDAQ:CDXS - TradingView
Price to book forward of Codexis, Inc. – LSX:A0Q2S4 - TradingView
Codexis, Inc. Actuals & Estimates (NASDAQ:CDXS) - TradingView
CDXS Forecast — Price Target — Prediction for 2027 - TradingView
Codexis Inc (CDXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Did CDXS Stock Jump 7% Today? - Stocktwits
Codexis Inc (CDXS) Institutional Confidence - TradingKey
Codexis, Inc. 2026 Annual Meeting Results: Shareholder Votes and SEC Filing Summary - Minichart
Codexis Shareholders Back Board Slate and Governance Measures - TipRanks
Form 8K Codexis Inc For: 22 June By Investing.com - Investing.com South Africa
Codexis shareholders elect directors and approve proposals at annual meeting - Investing.com Nigeria
Codexis (CDXS) shareholders back board nominees, KPMG and pay plan - Stock Titan
Codexis Inc (CDXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Codexis | 4: Statement of changes in beneficial ownership of securities-Director PARKER H STEWART - Moomoo
Codexis (CDXS) director Parker H. Stewart receives 66,350 stock options - Stock Titan
Codexis | 4: Statement of changes in beneficial ownership of securities-Director Collins Cynthia - Moomoo
Director at Codexis (CDXS) receives 66,350 stock options grant - Stock Titan
CODEXIS (CDXS) director receives 66,350 stock options at $2.48 strike price - Stock Titan
Codexis | 4: Statement of changes in beneficial ownership of securities-Director Smith David V - Moomoo
Codexis (CDXS) director David V. Smith granted 66,350 stock options at $2.48 - Stock Titan
Codexis (NASDAQ: CDXS) director receives 66,350 options vesting in one year - Stock Titan
Codexis (CDXS) director receives option grant for 66,350 shares - Stock Titan
Codexis (CDXS) grants director 66,350 stock options at $2.48 - Stock Titan
Codexis (CDXS) director Raymond De Vre awarded 66,350 stock options at $2.48 - Stock Titan
Codexis Inc (CDXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Codexis Inc (CDXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Codexis Inc (CDXS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Codexis Inc (CDXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Codexis Inc (CDXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Codexis Inc (CDXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CDXS: All proposals, including director elections and auditor ratification, were approved without contest - TradingView
Codexis Inc Annual Shareholders Meeting Transcript - GuruFocus
Cantor Fitzgerald reiterates Codexis stock rating on oligo platform - Investing.com
Cantor Fitzgerald reiterates Codexis stock rating on oligo platform By Investing.com - Investing.com Canada
CDXS Q1 2026 Earnings: EPS Beats Estimates as Company Shows Operational ProgressEPS Revision Trend - newsline.com
CDXS Stock Price, Quote & Chart - ChartMill
CDXS Q1 2026 Earnings: EPS Beats Estimates by 28.26% Despite Revenue UncertaintiesMargin Improvement Report - newsline.com
Codexis (CDXS) Hovers Near Support as Consolidation ContinuesExtension Target - newsline.com
Codexis director Raymond de Vre sells $6,173 in shares - Investing.com UK
Codexis director Raymond de Vre sells $6,173 in shares By Investing.com - Investing.com Nigeria
Codexis (CDXS) director De Vre sells 2,605 shares to cover RSU tax liability - Stock Titan
CDXS Q1 2026 Earnings: EPS Beat Despite Revenue Uncertainty, Shares SlipOperating Income Trends - newsline.com
CDXS Q1 2026 Earnings: EPS Surprise of 28% Fails to Offset Revenue UncertaintyEarnings Revision Downgrade - newsline.com
CDXS Q1 2026 Earnings: Narrower-Than-Expected Loss Signals ProgressProduct Revenue Analysis - newsline.com
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA - Caledonian Record
Codexis Inc. (CDXS) Posts Modest Gains, Hovers Between Key Support and Resistance LevelsSpring Pattern - newsline.com
Codexis Inc. (CDXS) Climbs 4.4% as Shares Approach Key ResistanceIron Condor Alert - The Legal Advocate
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Codexis Inc Stock (CDXS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lutz Stefan | Chief Scientific Officer |
Feb 24 '26 |
Sale |
1.13 |
5,862 |
6,641 |
130,421 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):